NCT03867487View on ClinicalTrials.gov

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

January 1, 2028

Study Completion Date

February 1, 2028

Conditions
Non-Alcoholic Fatty Liver DiseaseNAFLDPediatric NAFLD
Interventions
DRUG

Empagliflozin 10 MG

Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)

DRUG

Placebo Oral Tablet

Participants will take an identical appearing oral tablet with zero active ingredient.

Trial Locations (1)

60601

Ann & Robert H Lurie Children's Hospital of Chicago, Chicago

All Listed Sponsors
lead

Ann & Robert H Lurie Children's Hospital of Chicago

OTHER